Evidence map›Paper›PMID 41141080›Full record

ArticleCureus2025

Nivolumab-Induced Warm Autoimmune Hemolytic Anemia and Pancytopenia.

Matthew Baron, Fnu Amisha, Kiranpreet Kaur, Neha Verma

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Matthew BaronInternal Medicine, Moffitt Cancer Center, Tampa, USA.
Fnu AmishaOncology, Moffitt Cancer Center, Tampa, USA.
Kiranpreet KaurInternal Medicine, University of South Florida Morsani College of Medicine, Tampa, USA.
Neha VermaInternal Medicine, Moffitt Cancer Center, Tampa, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy-related adverse events arise from the disinhibition of the body's own immune system. A 76-year-old Caucasian man undergoing treatment with nivolumab monotherapy for metastatic clear cell renal carcinoma presented to our hospital with symptoms of fatigue and easy bruising. Laboratory analysis confirmed warm autoimmune hemolytic anemia with pancytopenia. Bone marrow biopsy demonstrated no evidence of malignancy or marrow failure. He was initiated on guideline-driven therapy with corticosteroids and experienced complete resolution of cytopenias by the three-month follow-up.

Indexed as

clear cell renal carcinomadrug-induced pancytopeniaimmunotherapy-related adverse eventsnivolumab-related adverse eventsnon-malignant hematologywarm autoimmune hemolytic anemia

Identifiers

PMID41141080
PMCPMC12547619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.